Price
Target price
€3.30
€3.30
-0.300%
-0.01
-0.300%
€10.73
09.06.25 / Frankfurt
WKN: A2AFXS / Symbol: CRVS / Name: Corvus / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Corvus Pharmaceuticals Inc Stock
The price for the Corvus Pharmaceuticals Inc stock decreased slightly today. Compared to yesterday there is a change of -€0.010 (-0.300%).
With 8 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
Based on the current price of 3.3 € the target price of 10 € shows a potential of 203.49% for Corvus Pharmaceuticals Inc which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Corvus Pharmaceuticals Inc stock. Criterium "Brand" gathered the most positive votes but regarding "Brand" there were negative voices in the community.
Pros and Cons of Corvus Pharmaceuticals Inc in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
S********** s********
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Corvus Pharmaceuticals Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Corvus Pharmaceuticals Inc | -0.300% | 3.768% | -18.496% | 76.549% | -31.996% | 213.270% | 22.407% |
| Krystal Biotech | 0.370% | 9.817% | 2.471% | -20.992% | -20.992% | 135.784% | - |
| Ardelyx Inc. | -1.210% | -3.988% | 0.186% | -46.035% | -35.025% | 412.470% | -50.369% |
| Evolus Inc | -0.610% | -2.941% | -6.780% | -25.000% | -21.429% | -27.632% | 55.660% |
Comments
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its price target lowered by analysts at Mizuho from $12.00 to $11.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $17.00 price target on the stock, up previously from $15.00.
Show more
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc..
Show more
Ratings data for CRVS provided by MarketBeat